Abstract
Leptin has received extensive attention as an endogenously produced satiety factor. Although once considered to be solely derived from adipose tissue, it is now apparent that leptin can be produced by various tissues including those comprising the cardiovascular system such as blood vessels and cardiomyocytes. Moreover, leptin receptors (OBR) have been identified in cardiovascular tissues. The increased cardiovascular risk associated with obesity is well known and many of the effects of leptin appear to be compatible with its potential role as a contributing factor to increased cardiovascular morbidity associated with obesity. Evidence from both animal and human studies implicated leptin as a potential contributor to the increased incidence of cardiovascular morbidity associated with hyperleptinemic conditions. This review focuses on some of the complex vascular actions of leptin and the emerging role of leptin as a cardiovascular regulator in terms of normal homeostatic function, but particularly in cardiovascular pathology.
Keywords: Leptin, vascular hypertrophy, vascular signaling, vascular remodeling, endothelium, angiogenesis, hypertension
Current Vascular Pharmacology
Title: Leptin and Vascular Smooth Muscle
Volume: 4 Issue: 4
Keywords: Leptin, vascular hypertrophy, vascular signaling, vascular remodeling, endothelium, angiogenesis, hypertension
Abstract: Leptin has received extensive attention as an endogenously produced satiety factor. Although once considered to be solely derived from adipose tissue, it is now apparent that leptin can be produced by various tissues including those comprising the cardiovascular system such as blood vessels and cardiomyocytes. Moreover, leptin receptors (OBR) have been identified in cardiovascular tissues. The increased cardiovascular risk associated with obesity is well known and many of the effects of leptin appear to be compatible with its potential role as a contributing factor to increased cardiovascular morbidity associated with obesity. Evidence from both animal and human studies implicated leptin as a potential contributor to the increased incidence of cardiovascular morbidity associated with hyperleptinemic conditions. This review focuses on some of the complex vascular actions of leptin and the emerging role of leptin as a cardiovascular regulator in terms of normal homeostatic function, but particularly in cardiovascular pathology.
Export Options
About this article
Cite this article as:
Leptin and Vascular Smooth Muscle, Current Vascular Pharmacology 2006; 4 (4) . https://dx.doi.org/10.2174/157016106778521634
DOI https://dx.doi.org/10.2174/157016106778521634 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Strategies to Improve the Functions and Redox State of the Immune System in Aged Subjects
Current Pharmaceutical Design Transcatheter Aortic Valve Implantation versus Surgical Aortic Valve Replacement: Meta-Analysis of Clinical Outcomes and Cost-Effectiveness
Current Pharmaceutical Design The Interplay between Indoleamine 2,3-Dioxygenase 1 (IDO1) and Cyclooxygenase (COX)-2 In Chronic Inflammation and Cancer
Current Medicinal Chemistry Myocardial Structure and Matrix Metalloproteinases
Current Topics in Medicinal Chemistry Mechanisms of Medial Arterial Calcification in Diabetes
Current Pharmaceutical Design Aldose Reductase, Oxidative Stress and Diabetic Cardiovascular Complications
Cardiovascular & Hematological Agents in Medicinal Chemistry microRNA Biogenesis Pathway as a Therapeutic Target for Human Disease and Cancer
Current Pharmaceutical Design The Antioxidants and Pro-Antioxidants Network: An Overview
Current Pharmaceutical Design Hepatocyte Growth Factor Attenuates the Development of TGF-β1- Induced EndMT through Down-regulating the Notch Signaling
Endocrine, Metabolic & Immune Disorders - Drug Targets Molecular Mechanisms of Inflammation. Anti-Inflammatory Benefits of Virgin Olive Oil and the Phenolic Compound Oleocanthal
Current Pharmaceutical Design Aminoacid Support in the Prevention of Diabetes and Diabetic Complications
Current Protein & Peptide Science Inhibition of Renin-Angiotensin System and Advanced Glycation End Products Formation: A Promising Therapeutic Approach Targeting on Cardiovascular Diseases
Cardiovascular & Hematological Agents in Medicinal Chemistry Influence of Impaired Liver Methionine Metabolism on the Development of Vascular Disease and Inflammation
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Mesenchymal Cells in the Treatment of Spinal Cord Injury: Current & Future Perspectives
Current Stem Cell Research & Therapy Meet Our Editorial Board Member
Letters in Drug Design & Discovery MicroRNAs: A Critical Regulator and a Promising Therapeutic and Diagnostic Molecule for Diabetic Cardiomyopathy
Current Gene Therapy Preeclampsia Emerging as a Novel Risk Factor for Cardiovascular Disease in the Offspring
Current Pediatric Reviews Metabolomics and the Diagnosis of Human Diseases -A Guide to the Markers and Pathophysiological Pathways Affected
Current Medicinal Chemistry Integrins: Novel Therapeutic Targets for Cardiovascular Diseases
Cardiovascular & Hematological Agents in Medicinal Chemistry Fine Tuning Therapeutic Targeting of the Sphingolipid Biosynthetic Pathway to Treat Atherosclerosis
Current Vascular Pharmacology